In 2019, the legislation expanded the NBS program to include CH, PKU, CF, GAL, biotinidase deficiency, CAH, hemoglobinopathies, and visual, hearing, and cardiac screening (Presidencia, 2019). The gene discussed is GAL; the disease is hemoglobinopathy.